Tirzepatide
GLP-1 + GIP dual receptor agonist (Mounjaro, Zepbound)
A first-in-class dual GLP-1 + GIP receptor agonist with substantially greater weight-loss efficacy than Semaglutide. FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). The GIP arm partitions nutrients toward muscle and improves insulin sensitivity beyond GLP-1 alone. Standard protocol uses 20-week titration.
Quick reference
How Tirzepatide works
Tirzepatide is the first dual GLP-1 + GIP receptor agonist in clinical use. The GLP-1 arm drives the same appetite-suppression and gastric-emptying mechanism as Semaglutide. The GIP arm is what makes Tirzepatide structurally different — GIP receptor activity partitions ingested nutrients preferentially toward muscle (vs fat storage) and improves insulin sensitivity beyond what GLP-1 alone delivers.
Mechanistically, this dual action explains the substantially greater weight-loss efficacy vs Semaglutide. SURMOUNT-1 trial (72 weeks at 15 mg): -22.5% bodyweight vs Wegovy STEP 1 (-14.9% at 2.4 mg). The GIP component also appears to reduce some of the GI side-effect burden at equivalent metabolic effect.
Half-life is ~120 hours (5 days), shorter than Semaglutide's 168 hours but still supporting weekly dosing. Steady-state plasma levels are reached in ~4 weeks.
In the DoseCraft framework, Tirzepatide directly addresses all three Root Causes: Insulin Resistance (most powerful improvement of any current peptide), Inflammation (GIP + GLP-1 pathways both reduce inflammatory cytokines), and ATP Shortage (improved insulin sensitivity → improved cellular fuel uptake).
Safety + side-effect profile
Side-effect profile is similar to Semaglutide but slightly milder at equivalent weight-loss efficacy. GI effects remain dominant, especially during titration.
Documented serious risks: pancreatitis (rare, <1%), gallbladder issues, MTC theoretical (FDA boxed warning — contraindicated in MEN-2 / family history of MTC). Contraindications: type 1 diabetes, severe gastroparesis, active gallbladder disease, pregnancy, breastfeeding.
Critical interactions: never stack with Semaglutide, Liraglutide, or Retatrutide — all are GLP-1 agonists, no added efficacy, compounded GI burden. Caution with sulfonylureas and insulin (hypoglycemia risk). Birth control absorption can be reduced during slow gastric emptying — use backup contraception during titration.
Lean mass preservation is the single biggest practitioner gap. Without resistance training + 1.6–2.2 g protein per kg per day, expect 30–40% of lost weight to be lean mass. With protocol, drops to 10–15%.
- • Nausea (less severe than Semaglutide on average; 30–40% in first 4 weeks)
- • Constipation more common than diarrhea
- • Reflux / GERD (especially if eating large meals)
- • Fatigue in first 2–4 weeks
- • Loss of food noise (intended effect)
- • Hand / foot mild fluid shifts during fast titration (transient)
Frequently asked
What is Tirzepatide?
Tirzepatide is a first-in-class dual GLP-1 + GIP receptor agonist. FDA-approved for type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound, 2023). Substantially greater weight-loss efficacy than Semaglutide because the GIP arm partitions nutrients toward muscle and improves insulin sensitivity beyond GLP-1 alone.
What's the standard Tirzepatide titration?
20-week titration: 2.5 mg × 4 weeks → 5 mg × 4 weeks → 7.5 mg × 4 weeks → 10 mg × 4 weeks → 12.5 mg × 4 weeks → 15 mg maintenance. For T2D, target is often 5–15 mg. For weight loss, target is 10–15 mg. Slow titration is critical to minimize GI side effects.
Tirzepatide vs Semaglutide — which is better?
For weight loss: Tirzepatide is meaningfully more powerful (SURMOUNT-1: -22.5% at 15 mg vs Wegovy STEP 1: -14.9% at 2.4 mg, both 68-72 weeks). For T2D glycemic control: similar efficacy at therapeutic doses but Tirzepatide tends to drop A1C more aggressively. Side-effect profile is slightly milder per unit of weight loss with Tirzepatide. Cost (out of pocket) is similar.
Can I stack Tirzepatide with Semaglutide or Retatrutide?
No. All three are GLP-1 receptor agonists (Retatrutide is a triple agonist adding glucagon receptor activity). Stacking compounds GI side effects with zero added efficacy. If you want to switch from Semaglutide to Tirzepatide, the standard transition is: stop Semaglutide → wait 2 weeks (Semaglutide's 168-hr half-life means residual binding) → start Tirzepatide at 2.5 mg.
How much weight can I lose on Tirzepatide?
SURMOUNT-1 (72 weeks at 15 mg): -22.5% of bodyweight. SURMOUNT-3 (intensive lifestyle + 15 mg): -26.6%. Practitioner reality: most users see 1.5–3 lbs/week during active titration, slowing to 0.5–1.5 lb/week at maintenance dose. The GIP component appears to support better lean mass preservation than Semaglutide alone.
What's the lean mass story with Tirzepatide?
GIP receptor activity partitions nutrients preferentially toward muscle, which appears to help lean-mass retention vs Semaglutide. Practitioner reports describe slightly better physique outcomes at equivalent weight loss. Still, resistance training + 1.6–2.2 g protein per kg per day is essential — without it, ~30% of lost weight is still lean mass.
Are there long-term safety concerns with Tirzepatide?
Currently ~3 years of cumulative safety data from the Mounjaro indication. Documented risks: pancreatitis (rare, <1%), gallbladder issues (similar rates to Semaglutide), MTC theoretical (FDA boxed warning, contraindicated in MEN-2 / family history). Long-term safety profile is expected to mirror Semaglutide's but is still maturing.
What happens when I stop Tirzepatide?
Like Semaglutide, weight regain is common without lifestyle intervention — SURMOUNT-4 trial showed 14% regain over 1 year after withdrawal. Practitioner approach: taper rather than stop cold, maintain protein + resistance training habits, and treat Tirzepatide as a chronic medication for chronic obesity rather than a short-term protocol.
Protocols using Tirzepatide
Outcome-driven stacks with phased dose schedules and cited PMIDs.
Head-to-head comparisons
Cited side-by-side breakdowns that include Tirzepatide.
Related compounds
Often researched, stacked, or compared with Tirzepatide.
Build your Tirzepatide protocol with Coach
Coach personalizes the dose, stack, and cycle for your specific goals — and saves the result as a cited PDF you can bring to your doctor. Free for 14 days.
Start 14-Day Free TrialNo credit card · cancel anytime